Ocular Therapeutix Files Annual 10-K, Details Strong Cash Position and AXPAXLI Clinical Progress

summarizeZusammenfassung

Ocular Therapeutix's annual 10-K filing provides a comprehensive overview of its financial performance and significant advancements in its clinical pipeline. While the company reported an increased net loss for 2025 and a decline in DEXTENZA product revenue, these are largely offset by substantial capital raises in 2024 and 2025, which have bolstered its cash reserves to $737.1 million and extended its operational runway into 2028. This strong liquidity position is critical for a biotech company heavily investing in R&D. The filing confirms significant progress in the AXPAXLI clinical programs, with the imminent presentation of SOL-1 Phase 3 Week 52 results, accelerated topline data for SOL-R, and the initiation of HELIOS-3. These milestones represent key value drivers for the company's future.

check_boxSchlusselereignisse

• Full Year 2025 Financial Results

  The company reported a net loss of $265.9 million for the year ended December 31, 2025, an increase from $193.5 million in 2024. Total revenue decreased to $51.9 million from $63.7 million in the prior year, primarily due to an 18.3% decline in DEXTENZA net product revenue. Research and development expenses significantly increased to $197.1 million, reflecting substantial investment in pipeline programs.

• Strong Liquidity and Extended Runway

  Ocular Therapeutix ended 2025 with $737.1 million in cash and cash equivalents, up from $392.1 million in 2024. This strong cash position, bolstered by a $445.6 million offering in October 2025 and $94.0 million from an ATM program in June 2025, is expected to fund operations into 2028.

• AXPAXLI Clinical Program Advancements

  All subjects in the SOL-1 Phase 3 trial for wet AMD completed their Week 52 visit, with results expected to be presented between February 25-28, 2026. The SOL-R Phase 3 trial for wet AMD completed randomization of 631 subjects in December 2025, with topline data now accelerated to Q1 2027. The HELIOS-3 Phase 3 trial for diabetic retinal disease was initiated in November 2025.

• DEXTENZA Performance and Pediatric Label Expansion

  Despite a revenue decline, in-market unit sales of DEXTENZA increased by approximately 5,000 units in 2025. The company received FDA approval for DEXTENZA's pediatric label expansion in April 2025, and separate reimbursement in ASC and HOPD settings is confirmed for 2026.

auto_awesomeAnalyse

Ocular Therapeutix's annual 10-K filing provides a comprehensive overview of its financial performance and significant advancements in its clinical pipeline. While the company reported an increased net loss for 2025 and a decline in DEXTENZA product revenue, these are largely offset by substantial capital raises in 2024 and 2025, which have bolstered its cash reserves to $737.1 million and extended its operational runway into 2028. This strong liquidity position is critical for a biotech company heavily investing in R&D. The filing confirms significant progress in the AXPAXLI clinical programs, with the imminent presentation of SOL-1 Phase 3 Week 52 results, accelerated topline data for SOL-R, and the initiation of HELIOS-3. These milestones represent key value drivers for the company's future.